rosiglitazone has been researched along with Burns in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adanichkin, N; Campbell, JM; Kurmis, R; Munn, Z | 1 |
| Dülger, GA; Gedik, N; Sehirli, AO; Sener, G | 1 |
1 review(s) available for rosiglitazone and Burns
| Article | Year |
|---|---|
Intensive insulin therapy, insulin sensitisers and insulin secretagogues for burns: A systematic review of effectiveness and safety.
Topics: Burns; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Exenatide; Glipizide; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Metformin; Pioglitazone; Rosiglitazone; Secretagogues; Sulfonylurea Compounds | 2018 |
1 other study(ies) available for rosiglitazone and Burns
| Article | Year |
|---|---|
Rosiglitazone, a PPAR-gamma ligand, protects against burn-induced oxidative injury of remote organs.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Burns; Female; Hypoglycemic Agents; Interleukin-1beta; Kidney Diseases; L-Lactate Dehydrogenase; Liver Diseases; Male; Malondialdehyde; Oxidative Stress; Peroxidase; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha; Urea | 2007 |